Today: July 31, 2015, 5:13 am
  
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors - new market research report published
companiesandmarkets.com
companiesandmarkets.com
Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors - a new market research report on companiesandmarkets.com

 

PR-Inside.com: 2014-03-14 09:00:03
Targeting kinases have been on the agenda of most drug developers/ researchers as they hold the key path to signaling, development and growth of the cell. Tumors/cancer biology indicates that this balance is disturbed and inhibiting the aberrant pathways in a balanced way is an approach to developing drugs against cancer.

Resistance to existing therapies develops as cancer cells bypass these efforts and their remains an evergreen search for new targets to meet these challenges. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years.

Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for unpartnered products as mature data and approvals come in the next few years.

Report Scope

This report (ToC attached) highlights the recent progress on the understanding of PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors (PCYC, INFI, CRIS, SymBio, GILD), the clinical data and competition.

Key Points Discussed in the Report

Drugs in the pipeline
PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD)
Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS)
BTK-inhibitors - Safety and clinical efficacy set it apart - Pharmacyclics (PCYC), Celgene (CELG)
M&A in Kinase Inhibitors in the last 5 years
Related Milestones/catalysts in 2013-14
Combination Studies - PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers.
Ongoing Clinical Trials of Companies Covered
Detailed Reports on -
Curis (CRIS) - Time to Assess Value Beyond Erivedge!
Gilead (GILD) - New HIV + HCV Products to Sustain the Growth Trajectory
Infinity pharma (INFI) - IPI-145, Unpartnered, Potent PI3K Inhibitor = Larger Opportunity!
Pharmacyclics (PCYC) - Ibrutinib - Promising to Deliver More
SymBio (4582) - Significant Upside still Remains: Bendamustine + Rigosertib + Cash to In-license More!

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Press Information


Published by
Mike King
London: +44 (0) 203 086 8600
e-mail
www.companiesandmarkets.com
Related Articles

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.